A head-to-head test in primary prevention
Atherosclerotic cardiovascular disease (ASCVD) remains one of the most important preventable causes of death worldwide. It accounts for heart attacks and ischemic strokes, and it often develops silently. The challenge for clinicians has always been deciding who should take a statin before an event occurs. Statins are proven to lower the risk of a first cardiovascular event, but the decision to start them rests on accurately estimating individual risk.
Two decision tools were compared in the CorCal Outcomes trial: the pooled cohort equations (PCE), a traditional risk calculator that uses conventional factors such as smoking, diabetes, hypertension and cholesterol, and coronary artery calcium (CAC) scoring, a CT-based measurement of the amount of calcified plaque in the coronary arteries. The study's goal was to see whether selecting patients for statins with one approach rather than the other leads to different rates of major cardiovascular events (MACE). According to results presented in a Hot Line session at ESC Congress 2026, the two strategies produced no difference in that outcome.
Why the calcium score is attractive
CAC scanning is not a measure of risk factors; it is a direct look at the burden of atherosclerosis in the heart's own arteries. In theory, seeing calcium provides a more individualized picture of whether plaque is present. That could be helpful for people whose risk-factor profile suggests they are at intermediate risk, or for younger adults who might not meet thresholds on traditional equations despite having early disease. The conference presentation notes that traditional tools may not flag certain younger individuals who nevertheless go on to have first heart attacks.
But an imaging-based approach has logistical and cost implications, and evidence is needed to show that acting on the test result actually improves clinical outcomes. The CorCal trial was specifically designed to compare the downstream effect of using either the PCE risk score or CAC score as the basis for a statin recommendation.
Study design
Investigators from Intermountain Medical Center recruited patients from the Canyons and Desert regions of Intermountain Health Care in the United States. Participants could not have established ASCVD, diabetes, or a history of statin therapy. They were randomized equally to have statin initiation guided by one of the two methods. In both arms, the protocol supplied a recommendation about whether to initiate a statin; however, the final decision was left to the patient and the treating physician.
- CAC-guided group: statin recommendation made after CT-based coronary artery calcium scoring.
- PCE-guided group: statin recommendation made using the pooled cohort equations based on traditional risk factors.
- Follow-up tracked major cardiovascular events.
This pragmatic design re-creates how these tools are used in routine care rather than locking a clinician into a mandated prescription.
Equivalent outcomes after statin initiation
The principal finding, presented in a Hot Line at ESC Congress 2026, was that there was no difference in major cardiovascular events between the two groups. In other words, starting statins based on CAC did not lead to fewer heart attacks, strokes, or other major events than starting statins based on PCE. That held despite the fact that CAC provides a direct assessment of coronary plaque burden. The result may surprise proponents of advanced imaging who hoped that a more precise anatomical measure would translate into better clinical results.
This comparison highlights a wider issue: the relationship between a diagnostic strategy and the downstream treatment it triggers. If the resulting statin use is similar, event rates are likely to be similar too. The no-difference finding does not mean CAC lacks value; rather, it means the two decision frameworks produced comparable outcomes for the primary prevention population enrolled in the trial.
Clinical implications for risk assessment gaps
Dr. Joseph B. Muhlestein of Intermountain Medical Center, the trial's principal investigator, underscored a well-known clinical blind spot: “For far too many patients, the first symptom of ASCVD is a heart attack.” He said statins are highly effective for prevention, but there remains a substantial gap in risk assessment, statin initiation and statin persistence. In particular, some younger adults who later experience a first heart attack would not have been identified as high risk by current tools.
The CorCal result suggests that as a strategy for initiating statins in people without known disease or diabetes, CAC-based guidance performs on par with the traditional PCE approach. It also raises questions about how to incorporate patient preferences, cost, and radiation exposure into the choice of assessment method. Both strategies may be acceptable when incorporated into a shared decision-making framework, according to the findings as presented.
Moving prevention forward
These results are relevant to clinicians and health systems thinking about how to allocate resources for cardiovascular screening. Since no difference in MACE was observed, payer and policy discussions may focus on the real-world value of adding CAC CT scans to routine risk assessment. On the other hand, CAC may still identify patients who would have been missed by traditional risk factor calculators, particularly younger adults, and future research may refine how the calcium score is used.
The CorCal Outcomes trial did not present detailed subgroup numbers in the release, but the main end point answers an important comparison question at the strategy level. Newer approaches to risk assessment are often used before their effect on patient outcomes is fully known; the trial offers a more sober test by linking the assessment tool to the clinical decisions it generates.
Dr. Muhlestein's observation that heart attack remains an initial symptom for too many patients is a reminder that the goal of prevention is not simply to categorize risk, but to close the gap between identifying who may be vulnerable and actually beginning effective therapy. The CorCal trial suggests that, in a clinical setting where final treatment decisions remain patient- and physician-driven, neither guiding strategy outperformed the other on cardiovascular events.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
